32 results
424B5
GLUE
Monte Rosa Therapeutics Inc
26 Oct 23
Prospectus supplement for primary offering
4:55pm
attestation requirement in the assessment of our internal control over financial reporting.
We may take advantage of these exemptions until … approval of any golden parachute arrangements not previously approved; and
an exemption from the auditor attestation requirement in the assessment
8-K
EX-99.4
GLUE
Monte Rosa Therapeutics Inc
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
) Observed dose dependent PK after oral dosing Clinical data support that 0.5 mg starting dose was fully active based on pharmacodynamic (PD) assessment … support that 0.5 mg starting dose was active based on PD assessment (PBMC and tissue), with optimal PD modulation across dose levels tested Encouraging
8-K
EX-99.3
sw8 y0urvx
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am
PRE 14A
huc3quemh07dtz
12 Apr 23
Preliminary proxy
4:07pm
S-3
EX-4.6
m8e86i
1 Jul 22
Shelf registration
5:01pm
S-3
EX-4.5
ct69t1ma
1 Jul 22
Shelf registration
5:01pm
S-3
d4m nx2jwdlwml
1 Jul 22
Shelf registration
5:01pm
DEF 14A
watcbvng4ktymga0sc3
27 Apr 22
Definitive proxy
4:10pm
10-K
iqkq0s
29 Mar 22
Annual report
4:15pm
10-K
EX-10.20
igzt0sm6r
29 Mar 22
Annual report
4:15pm
10-Q
9xq3e0 0k32
12 Aug 21
Quarterly report
4:22pm
424B4
qoa7tlnggzgouauqr
25 Jun 21
Prospectus supplement with pricing info
6:08am